Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: J Heart Lung Transplant. 2023 Aug 5;42(12):1666–1677. doi: 10.1016/j.healun.2023.08.001

Table 1.

Study participant demographics

Cohort Study (N = 106) Sub-set analysis (N = 24)
Normal Telomere (N = 49) Short Telomere (N = 57) Normal Telomere (N = 11) Short Telomere (N = 13)
Male (%) 38 (78%) 44 (77%) 9 (82%) 8 (62%)
Age (Median, Range) 64 (44–74) 61 (43–76) 62 (55 – 70) 55(45–69)
Double lung 43 (88%) 44 (77%) 10 (91%) 11 (85%)
Induction:
  basiliximab 25 (51%) 29 (51%) 8 (73%) 10 (77%)
  alemtuzumab 24 (49%) 28 (49%) 3 (27%) 3 (23%)
Telomere length*
  <1 0 19 0 9
  1–10 0 38 0 4
  10–50 42 0 8 0
  >50 7 0 3 0
Genetic Testing 26 (53%) 40 (70%) 5 (45%) 8 (62%)
  Variant Identified 5(19%) 21(53%) 2 (40%) 5 (63%)
CMV Donor + 32 (65%) 43 (75%) 7 (64%) 9 (69%)
*

Lymphocyte telomere length reported as age-adjusted percentile